1 / 21

Clinical Use of Coagulation Inhibitors

PHM142 Fall 2013 Instructor: Dr. Jeffrey Henderson. Clinical Use of Coagulation Inhibitors. By: Jonathan Mak , Elsa Chien , Anna Guo PHM 142 – Biochemistry September 18 th , 2013. Introduction. Coagulation (Thrombogenesis)  Process of clots formation (blood vessels)

shaun
Download Presentation

Clinical Use of Coagulation Inhibitors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PHM142 Fall 2013 Instructor: Dr. Jeffrey Henderson Clinical Use of Coagulation Inhibitors By: Jonathan Mak, Elsa Chien, Anna Guo PHM 142 – Biochemistry September 18th, 2013

  2. Introduction • Coagulation (Thrombogenesis)  Process of clots formation (blood vessels)  Homeostasis (prevent blood loss)  Use of platelet and fibrin-containing clots to stop bleeding  Hemorrhage vs. Thrombosis

  3. Mechanism of Coagulation

  4. Physiology • Platelet Activation • Damage to endothelium • Exposure of collagen to circulating platelets • Extrinsic pathway (tissue factor pathway) • Intrinsic pathway (contact activation pathway) • Thrombin Activates • Factor XI • Factor VIII • Factor V • Factor XIII • Fibrinogen to Fibrin

  5. Anticoagulants • Used to prevent cerebral and systemic emboli (blockage) in patients with: • acute myocardial infarction • valvular and non-valvular atrial fibrillation (arrhythmia) • prosthetic cardiac valves • Risk of excess bleeding • Most commonly used anticoagulants: warfarin, heparin

  6. Vitamin K Antagonists

  7. Vitamin K Antagonists • Reduce blood clotting by inhibiting vitamin K epoxide reductase • Therefore vitamin K epoxide cannot be reduced to the active form of vitamin K

  8. Vitamin K Antagonists • 4 of 13 clotting factors require Vitamin K as a cofactor to undergo gamma carboxylation • When factors are not carboxylated, they cannot bind to the phospholipid membrane. The clot doesnt form. • Action can be reversed by administering vitamin K • avoid foods rich in vitamin K (i.e. leafy green vegetables such as kale and etc) • *remembering that vitamin K antagonists stop conversion of oxidized K epoxide to the reduced vitamin K • Teratogen  can cause birth defects therefore contraindicated in pregnancy • Subgroups: • coumarins(i.e. warfarin) • Non coumarins (i.e. fluindione, phenidione)

  9. Warfarin • Vitamin K Antagonist (VKA) • interferes with hepatic synthesis of coagulation factors II, VII, IX, and X and anticoagulant proteins C and S • Widely prescribed for prevention of stroke in patients with atrial fibrillation (53% reduction in risk with anticoagulation compared to aspirin and placebo group in patients with NVAF non valvular atrial fibrillation) • Narrow therapeutic index and thus requires routine monitoring • Dose determined by looking at: • Prothrombin time (PT): Time it takes for blood to clot after addition of a tissue factor. Normal PT without warfarin is usually 12-15 seconds • International normalized ratio (INR): mathematical manipulation of one’s PT based on a sensitivity standard accounting for differences in batches of tissue factor. Target INR 2.5. • Taken once daily • Peak effect 72-96 hours • Associated with multiple drug interactions like • Aspirin, Omeprazole and Cimetidine increase its effects • Penicillin and SSRI decrease its effects • Overdose: take vitamin K1 orally or parenterally

  10. Quantitative Goals of PT/INR • Generally • INR = (PT test/PT normal) ^ ISI • ISI = value specific to tissue factor • INR= 2.0-3.0 (Generally people on the drug should be an INR of 2.0-3.0 for the purpose of thinning blood, but for people with artificial heart valves or with high risk of clot formation, an INR of 2.5-3.5 is used) • INR is used to adjust dose until the desired dose of medication is found. • INR < 2 generally results in thrombosis • INR >4.5 increased risk of bleeding • PT is measured both before use as a reference and then compared after the third day of anti-coagulant use. If there is a supratherapeutic indication, dose should be decreased. If stable, then more clinical tests are done over time to monitor any changes in PT. • PT of patient is compared against an average reference value based on people living in the area

  11. Heparin and derivatives of heparin

  12. Heparin • preparation of sulfated mucopolysaccharide injected IV or SC • Found in secretory granules of mast cells and released into vasculature at sites of tissue injury  main purpose as defense instead of anticoagulation. • Two forms: unfractionated heparin and low molecular weight heparin (nadroparin) • Onset: rapid • Overdose: Take protamine sulfate • Risks: heparin induced thrombocytopenia 1% - 5% of patients receiving heparin • Type 1: heparin associated thrombocytopenia (HAT), early onset (within 48-72h) • Non immune cause of disorder • Does not cause an increased risk of thrombosis • Resolves itself after a few days • Type II (HIT): 5-10 days after • Associated with immune response and activation of platelets • High risk of thromboembolic events • Require direct thrombin inhibitors to prevent thrombosis

  13. Unfractionated Heparin • 15000 daltons • Dosage: given frequently or as a continuous infusion (preferred). • Narrow therapeutic index and significant risk of bleeding • Indirect thrombin inhibitor that increases endogenous antithrombin activity

  14. Unfractionated Heparin Mechanism of action • Heparin binds to thrombin via exosite 2. This heparin-thrombin complex then binds to antithrombin which activates antithrombin and induces a conformational change. This ultimately inactivates thrombin and other proteases involved with blood clotting such as factor Xa. The heparin-antithrombin complex inactivates activated coagulation factors II, VII, IX, X, XI, XII, kallikrein and plasmin

  15. Low molecular weight heparin (nadroparin) • 3500 – 8000 daltons • Dosing: once or twice daily via deep subcutaneous injection • MoA: Through a conformational change in antithrombin III, it inhibits activated coagulation factor Xa • This is done more efficiently than the inhibition of thrombin (factor IIa) • This is why there are less side effects because factor Xa acts earlier in the coagulation cascade than thrombin

  16. Direct Factor Xa inhibitors: Apixaban • Recommended dose is 5 mg twice daily; Taken Orally • Direct and highly selective active site inhibitor of Factor Xa. It does not require antithrombin III like heparin for AT activity. • Inhibits free and clot bound factor Xa and prothrombinase activity. • Indirectly inhibits platelet aggregation induced by thrombin • Contraindicated in patients with artificial heart valves

  17. Direct Thrombin Inhibitor: Dabigatran • Orally active direct thrombin inhibitor DTI • Blocks conversion of fibrinogen into fibrin • Favored over warfarin for stroke prevention in patients with atrial fibrillation not caused by valvular problems • Contraindicated in patients with artificial heart valves • Onset: 2 hours • Dosage: 150 mg twice a day

  18. Site of Action

  19. Summary Slide • Coagulation is the process of blood clots formation, also known as thrombogenesis. It is used by the body to maintain hemostasis • Anticoagulants are used to prevent blood clots formation in patients with MI, arrhythmia, and prosthetic cardiac valves • Warfarin is a vitamin K antagonist (VKA) and interferes with hepatic synthesis of coagulation factors II, VII, IX, and X • Anticoagulant use is regularly monitored by the PT/INR test. INR levels are usually kept between 2.0 and 3.0. • INR<2.0 will likely result in thrombosis • INR>4.5 will likely result in excessive bleeding • Heparin is an indirect thrombin inhibitor which increases endogenous antithrombinactivity • Apixabanis a direct factor Xainhibitor • Dabigatranis a direct thrombin inhibitor.

  20. Reference • Adam, S.S., McDuffie, J.R., Lachiewicz, P.F., Ortel, T.L., & Williams, J.W. (2013). Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knew replacemnt: a systematic review. Annals of Internal Medicine, 159(4): 275-284. doi: 10.7326/0003-4819-159-4-201308200-00008 • Bounameaux, H. (1998). Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism. Vascular Medicine, 3 (41). Doi: 10.1177/1358836X9800300109 • Canadian Public Health Association (CPHA). (2012). Compendium of Pharmaceuticals and Specialties. Canada, 2012 edition. • Choudhury, A., Goyal, D., & Lip, G.Y.H. (2006). Ximelagatran. Drugs of Today, 42 (1). Pp. 3-19. ISSN 1699-3993. doi: 10.1358/dot.2006.42.1.893611 • Colman, R.W., Clowes, A.W., George, J.N., Goldhaber, S.Z., & Marder, V.J. eds. Overview of hemostasis. In: Hemostasis and Thrombosis: basic Principles and Clinical Practice, 5th edition. Philadelphia, Pa: JB Lippincott Co; 2006: 3-16 • Deloughery, T. (2013). Warfarin continuation was better than heparin bridging during pacemarker or ICD surgery. Annals of Internal Medicine, 159 (4): JC7. doi: 10.7326/0003-4819-159-4-201308200-02007 • Marlar R. & Saenko, E.L., (2013). Blood Coagulation & Fibrinolysis. WoltersKluwer Health. 24 (6), pp. 56 • O’Donnell, J. (2012). Anticoagulants: Therapeutics, Risks, and Toxicity – Special Emphasis on Heparin-Induced Thrombocytopenia (HIT). Journal of Pharmacy Practice, 25 (1). Pp. 22-29. doi: 10.1177/0897190011431146 • Pourrat, O., Neau, J.P., Pouget-Abadie, J.F., & Pierre, F. (2013). Thrombosis risk during pregnancy after history of cerebral venous thrombosis. Revue de Medecine Interne. pii: S0248-8663(13)00625-5. doi: 10.1016/j.revmed.2013.08.002 • Rabkin, M. Anticoagulation. Retrieved from http://www.medicineclinic.org/AmbulatorySyllabus4/NEW%20anticoagulation.htm

More Related